2025-04-06 00:08:51
Latest Post
Sai Life Sciences sets up Peptide Research Center in India
Netweb Technologies Ltd receives PLI Incentive Under IT Hardware Scheme 2.0
BHEL signs contract for ± 800 kV, 6000 MW Bhadla-Fatehpur LCC HVDC Terminal Station along with AC Transmission at Bhadla and Fatehpur
DEE Development Engineers Limited receives order worth approx. Rs. 55 crores- SURATWWALA BUSINESS GROUP Ltd purchases new commercial office space
Stock Report
Gland Pharma Ltd Q2FY25 consolidated profit up QoQ at Rs. 163.53 crores
Posted On : 2024-11-04 19:37:06( TIMEZONE : IST )
Gland Pharma Limited has reported Consolidated financial results for the period ended September 30, 2024.
Financial Results (Q2 FY2025) - QoQ Comparison
The company has reported total income of Rs. 1465.492 crores during the period ended September 30, 2024 as compared to Rs. 1453.136 crores during the period ended June 30, 2024.
The company has posted net profit / (loss) of Rs. 163.532 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs. 143.761 crores for the period ended June 30, 2024.
The company has reported EPS of Rs. 9.93 for the period ended September 30, 2024 as compared to Rs. 8.73 for the period ended June 30, 2024.
| Financials | Q2 FY2025 | Q1 FY2025 | % Change |
| Total Income | ₹ 1465.492 crs | ₹1453.136 crs |  0.85% |
| Net Profit | ₹163.532 crs | ₹143.761 crs | 13.75% |
| EPS | ₹9.93 | ₹8.73 | 13.75% |
Financial Results (Q2 FY2025) - YoY Comparison
The company has reported total income of Rs. 1465.492 crores during the period ended September 30, 2024 as compared to Rs.1426.579 crores during the period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.163.532 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs.194.082 crores for the period ended September 30, 2023.
The company has reported EPS of Rs.9.93 for the period ended September 30, 2024 as compared to Rs.11.78 for the period ended September 30, 2023.
| Financials | Q2 FY2025 | Q2 FY2024 | % Change |
| Total Income | ₹ 1465.492 crs | ₹1426.579 crs | 2.73% |
| Net Profit | ₹163.532 crs | ₹194.082 crs |  -15.74% |
| EPS | ₹9.93 | ₹11.78 | -15.70% |
Financial Results (Half Year Ended FY2025) - YoY Comparison
The company has reported total income of Rs.2918.628 crores during the 6 Months period ended September 30, 2024 as compared to Rs.2672.814 crores during the 6 Months period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.307.293 crores for the 6 Months period ended September 30, 2024 as against net profit / (loss) of Rs.388.184 crores for the 6 Months period ended September 30, 2023.
The company has reported EPS of Rs.18.65 for the 6 Months period ended September 30, 2024 as compared to Rs.23.56 for the 6 Months period ended September 30, 2023.
| Financials | Half Year Ended FY2025 | Half Year Ended FY2024 | % Change |
| Total Income | ₹2918.628 crs | ₹2672.814 crs | 9.20% |
| Net Profit | ₹307.293 crs | ₹388.184 crs | -20.84% |
| EPS | ₹18.65 | ₹23.56 | -20.84% |
Shares of Gland Pharma Limited was last trading in BSE at Rs. 1609.85 as compared to the previous close of Rs. 1644.85. The total number of shares traded during the day was 6858 in over 543 trades.
The stock hit an intraday high of Rs. 1650.00 and intraday low of 1602.35. The net turnover during the day was Rs. 11118196.00.
